<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>28017552</identifier>
<setSpec>1989-4805</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>de Santiago Nocito, A</dc:author>
<dc:author>Brotons Cuixart, C</dc:author>
<dc:author>Castro, A</dc:author>
<dc:author>Sans, S</dc:author>
<dc:author>Villar Alvarez, F</dc:author>
<dc:author>Baeza, C</dc:author>
<dc:author>Campos, P</dc:author>
<dc:author>Pérez, A</dc:author>
<dc:author>Alegría, E</dc:author>
<dc:author>Herranz, M</dc:author>
<dc:author>Maiques, A</dc:author>
<dc:author>Cortés, O</dc:author>
<dc:author>Cammafort Babkowski, M</dc:author>
<dc:author>Lobos Bejarano, J M</dc:author>
<dc:author>Royo-Bordonada, M Á</dc:author>
<dc:author>Pedro-Botet, J</dc:author>
<dc:author>Armario, P</dc:author>
<dc:author>Elosua, R</dc:author>
<dc:author>Serrano, B</dc:author>
<dc:author>Gil Núñez, A</dc:author>
<dc:description xml:lang="en">The VI European Guidelines for Cardiovascular Prevention recommend combining population and high-risk strategies with lifestyle changes as a cornerstone of prevention, and propose the SCORE function to quantify cardiovascular risk. The guidelines highlight disease specific interventions, and conditions as women, young people and ethnic minorities. Screening for subclinical atherosclerosis with noninvasive imaging techniques is not recommended. The guidelines distinguish four risk levels (very high, high, moderate and low) with therapeutic objectives for lipid control according to risk. Diabetes mellitus confers a high risk, except for subjects with type 2 diabetes with less than &lt;10 years of evolution, without other risk factors or complications, or type 1 diabetes of short evolution without complications. The decision to start pharmacological treatment of arterial hypertension will depend on the blood pressure level and the cardiovascular risk, taking into account the lesion of target organs. The guidelines don't recommend antiplatelet drugs in primary prevention because of the increased bleeding risk. The low adherence to the medication requires simplified therapeutic regimes and to identify and combat its causes. The guidelines highlight the responsibility of health professionals to take an active role in advocating evidence-based interventions at the population level, and propose effective interventions, at individual and population level, to promote a healthy diet, the practice of physical activity, the cessation of smoking and the protection against alcohol abuse.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Hypertension</dc:subject>
<dc:subject>Prevention and control</dc:subject>
<dc:subject>Tabaco</dc:subject>
<dc:subject>Diabetes mellitus</dc:subject>
<dc:subject>Hipertensión arterial</dc:subject>
<dc:subject>Grasas trans</dc:subject>
<dc:subject>Alcohol drinking</dc:subject>
<dc:subject>Cholesterol</dc:subject>
<dc:subject>Guías de práctica clínica</dc:subject>
<dc:subject>Tobacco</dc:subject>
<dc:subject>Consumo de alcohol</dc:subject>
<dc:subject>Practice Guidelines [Publication Type]</dc:subject>
<dc:subject>Colesterol</dc:subject>
<dc:subject>Enfermedades cardiovasculares</dc:subject>
<dc:subject>Cardiovascular diseases</dc:subject>
<dc:subject>Trans fatty acids</dc:subject>
<dc:subject>Prevención y control</dc:subject>
<dc:date>2017 Jan - Mar </dc:date>
<dc:title xml:lang="es">Adaptación española de las guías europeas de 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica.</dc:title>
<dc:title xml:lang="en">[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice].</dc:title>
<dc:publisher>Hipertension y riesgo vascular</dc:publisher>
</metadata>
</record>
</pubmed-document>
